World's largest eye-care device maker, selling contact lenses, eye-drops and cataract/vision-correction surgical equipment.
World's largest eye-care device maker, selling contact lenses, eye-drops and cataract/vision-correction surgical equipment.
Sells the machines used in cataract surgery plus the single-use implants and packs consumed with each operation, which repeat as procedures grow, while contact lenses and eye drops go through eye-care professionals and retail chains. Spun out of Novartis in 2019; Swiss-domiciled and listed in Zurich and New York.
In one line: A pure-play, larger Bausch + Lomb.
Moat: narrow (brand, installed base, switching costs). Surgeons trained on Alcon's cataract platforms and a broad lens/drop range create switching costs and R&D scale.
Headquarters: Geneva, Switzerland · Founded: 1945 · Employees: 25,942
Size Alcon (ALC.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $36.9B, the 16th largest of 155 Switzerland companies the cockpit tracks. Shares closed at CHF 62.32 on 18 Nov 2026.
Performance Over six months the shares gained 17.5%, against +26.7% for the median peer and +9.3% for the Switzerland market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 1.1% over the last twelve months (peer median +8.7%); the operating margin is 11.6% (peer median 21.2%).
Valuation It trades at 21.5× forward earnings against a peer median of 27.8× (6th cheapest of 21).
Price implies For today's price to make sense, revenue must grow about 12% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +6 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 1.8 points below its cost of capital (5.7% WACC).
Credit Alcon has 2 bonds outstanding ($1.11B), rated BBB+ by the agencies and trading like A at a weighted spread of 75 bp.
Next results Next results expected around 2 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CHF 8.75B | CHF 8.64B | CHF 8.73B | CHF 8.50B | CHF 8.33B |
| Revenue growth | — | -1% | +3% | +2% | — |
| Gross profit | CHF 5.05B | CHF 4.77B | CHF 4.86B | CHF 4.72B | CHF 4.59B |
| EBITDA | CHF 2.00B | CHF 2.24B | CHF 2.30B | CHF 2.16B | CHF 2.01B |
| Net income | CHF 533M | CHF 814M | CHF 897M | CHF 875M | CHF 320M |
| Free cash flow | CHF 1.48B | CHF 1.44B | CHF 1.41B | CHF 656M | CHF 555M |
| Capital expenditure | CHF 550M | CHF 551M | CHF 590M | CHF 765M | CHF 712M |
| Total debt | CHF 4.46B | CHF 4.16B | CHF 4.66B | CHF 4.33B | CHF 4.70B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Alcon ALC.SW | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% |
| Johnson & Johnson JNJ | $656B | +20% | +8% | 26% | 24.2× | 3.7% |
| Bausch + Lomb BLCO.TO | $7.41B | +35% | +11% | 9% | 18.3× | 12.0% |
| Cooper Companies (The) COO | $11.6B | -2% | +5% | 19% | 13.4× | 9.4% |
| Carl Zeiss Meditec AFX.DE | $3.17B | +22% | 0% | 8% | 24.4× | 12.5% |
| EssilorLuxottica EL.PA | $91.9B | +5% | +8% | 12% | 24.8× | 18.4% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ALC.SW | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +11.8% | +6.1% | 6th highest of 21 |
| 6-month return | +17.5% | +26.7% | 7th lowest of 21 |
| Distance from 52-week high | -8.8% | -7.0% | 9th lowest of 21 |
| Revenue growth (TTM) | +1.1% | +8.7% | 2nd lowest of 21 |
| Operating margin | 11.6% | 21.2% | 3rd lowest of 21 |
| Forward P/E | 21.5× | 27.8× | 6th cheapest of 21 |
| Growth the price implies (Req g, 7 yrs) | 12.2% | 16.0% | 8th least demanding of 21 |
| Growth delivered (Del g) | +6.1% | +9.4% | 8th lowest of 21 |
| Hurdle (Req g minus delivered) | +6.1 pp | +3.7 pp | 9th most demanding of 21 |
| ROIC minus cost of capital | -1.8 pp | +5.0 pp | 3rd lowest of 21 |
| EV / EBITDA | 17.0× | 22.6× | 8th cheapest of 20 |
| Net debt / EBITDA | 1.5× | 0.9× | 9th most indebted of 20 |
| Bond spread | 75 bp | 77 bp | 3rd tightest of 9 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Alcon ALC.SW | Switzerland | $36.9B | +18% | +1% | 12% | 21.5× | 12.2% | +6.1% |
| GE HealthCare GEHC | United States | $37.8B | +30% | +7% | 14% | 15.6× | 5.0% | +3.7% |
| Mettler Toledo MTD | United States | $34.6B | +60% | +7% | 29% | 33.7× | 20.1% | +5.5% |
| ResMed RMD | United States | $34.1B | +16% | +9% | 34% | 19.7× | 5.7% | +12.1% |
| Shenzhen Mindray Bio-Medical Electronics 300760.SZ | China | $33.6B | +15% | +5% | 28% | 27.3× | 1.0% | +9.7% |
| Illumina ILMN | United States | $31.8B | +48% | +6% | 21% | 35.2× | 27.2% | +6.0% |
| Dexcom DXCM | United States | $30.8B | +16% | +13% | 24% | 28.0× | 19.6% | +19.3% |
| Waters WAT | United States | $45.8B | +37% | +81% | 10% | 29.1× | 48.1% | +6.0% |
| West Pharmaceutical Services WST | United States | $28.1B | +32% | +13% | 23% | 40.2× | 25.8% | +7.4% |
| Hoya 7741.T | Japan | $49.0B | -16% | +13% | 32% | 27.7× | 14.1% | +11.6% |
| Agilent Technologies A | United States | $50.0B | +56% | +9% | 24% | 27.0× | 23.3% | +5.4% |
| Medline MDLN | United States | $51.5B | +8% | +12% | 6% | 25.6× | 15.9% | +9.9% |
| Siemens Healthineers SHL.DE | Germany | $53.7B | +27% | +1% | 14% | 18.9× | 9.6% | +5.6% |
| Steris STE | United States | $25.2B | +21% | +8% | 20% | 21.9× | 14.0% | +13.8% |
| Idexx Laboratories IDXX | United States | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% | +9.7% |
| Sartorius Stedim Biotech DIM.PA | France | $24.2B | +32% | +4% | 19% | 45.7× | 33.4% | +9.2% |
| Terumo 4543.T | Japan | $24.0B | +32% | +15% | 17% | 27.8× | 8.8% | +13.0% |
| Becton Dickinson BDX | United States | $58.9B | +48% | -7% | 16% | 16.3× | -1.6% | +0.3% |
| Edwards Lifesciences EW | United States | $60.5B | +27% | +13% | 29% | 32.3× | 17.1% | +6.7% |
| Boston Scientific BSX | United States | $63.3B | -23% | +9% | 21% | 14.1× | 5.8% | +15.2% |
| Straumann STMN.SW | Switzerland | $20.4B | +20% | +2% | 21% | 32.9× | 16.2% | +12.8% |
Alcon has 2 bonds outstanding with $1.11B face value. The agencies rate it BBB+; its bonds trade like A. Weighted yield 3.85%, a spread of 75 bp over government bonds.